Brokers Set Expectations for NBIX FY2025 Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Cantor Fitzgerald issued their FY2025 earnings estimates for Neurocrine Biosciences in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings of $5.83 per share for the year. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $3.93 per share.

NBIX has been the subject of several other research reports. William Blair restated an “outperform” rating on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Raymond James reaffirmed an “outperform” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Barclays lifted their target price on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the company an “overweight” rating in a research note on Monday, December 23rd. BMO Capital Markets dropped their price target on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a report on Thursday, October 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $190.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Five investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $164.81.

Neurocrine Biosciences Trading Up 1.8 %

NASDAQ NBIX opened at $145.88 on Wednesday. Neurocrine Biosciences has a 1-year low of $110.95 and a 1-year high of $157.98. The company has a market capitalization of $14.77 billion, a price-to-earnings ratio of 39.11 and a beta of 0.33. The stock’s 50 day moving average is $132.17 and its two-hundred day moving average is $131.15.

Hedge Funds Weigh In On Neurocrine Biosciences

Several hedge funds have recently modified their holdings of NBIX. Linden Thomas Advisory Services LLC boosted its position in Neurocrine Biosciences by 4.8% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 6,350 shares of the company’s stock valued at $867,000 after purchasing an additional 289 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in shares of Neurocrine Biosciences by 52.8% in the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 54,425 shares of the company’s stock valued at $7,429,000 after buying an additional 18,797 shares during the last quarter. Exchange Traded Concepts LLC grew its stake in shares of Neurocrine Biosciences by 2.1% in the fourth quarter. Exchange Traded Concepts LLC now owns 8,133 shares of the company’s stock valued at $1,110,000 after buying an additional 169 shares in the last quarter. Whalen Wealth Management Inc. acquired a new position in Neurocrine Biosciences during the fourth quarter worth $264,000. Finally, Janney Montgomery Scott LLC raised its position in Neurocrine Biosciences by 7.0% during the fourth quarter. Janney Montgomery Scott LLC now owns 17,545 shares of the company’s stock worth $2,395,000 after acquiring an additional 1,150 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Insider Buying and Selling

In related news, CEO Kyle Gano sold 65,000 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $141.50, for a total transaction of $9,197,500.00. Following the completion of the transaction, the chief executive officer now directly owns 135,392 shares in the company, valued at approximately $19,157,968. This trade represents a 32.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Ingrid Delaet sold 272 shares of Neurocrine Biosciences stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $138.10, for a total transaction of $37,563.20. Following the completion of the sale, the insider now owns 2,507 shares in the company, valued at $346,216.70. The trade was a 9.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 68,694 shares of company stock valued at $9,676,730 over the last three months. Company insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.